Concepedia

Author

Virginie Kerbusch

Astellas Pharma (Netherlands)

Also Known As

John Meijer, Virginie Kerbusch, Virginie M. M. Kerbusch

17

Publications

394

Citations

12

H-Index

29

Concepts

All Affiliations

Astellas Pharma (Netherlands)PharmAccess GroupAstellas Pharma (Japan)Astellas Pharma (United States)
VK

About

Virginie Kerbusch is an author at Astellas Pharma (Netherlands) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

256

2

Public Health

1

1

22

3

Biochemistry

1

1

39

4

Cell Biology

1

1

25

5

Cellular Physiology

1

1

25

Virginie Kerbusch

×

13

Publications

394

Citations

12

H-Index

YearCitations

Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee,

Clinical Therapeutics

2012

96

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder

Charlotte Eltink, Jennifer Lee, Marloes Schaddelee,

International Journal of Clinical Pharmacology and Therapeutics

2012

54

Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist

Jennifer Lee, Selina Moy, John Meijer,

Clinical Drug Investigation

2013

39

Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron

James Dickinson, Michaelene Lewand, Taiji Sawamoto,

Clinical Drug Investigation

2012

30

Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β<sub>3</sub>-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems

Shin Takusagawa, Fumihiko Ushigome, Hiroyuki Nemoto,

Molecular Pharmaceutics

2013

25

An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron‐Induced Cardiovascular Effects

Marcel van Gelderen, Matthias Stölzel, John Meijer,

The Journal of Clinical Pharmacology

2017

25

Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives

Monique Groen-Wijnberg, Jan van Dijk, Walter Krauwinkel,

European Journal of Drug Metabolism and Pharmacokinetics

2016

24

Effects of Food Intake on the Pharmacokinetic Properties of Mirabegron Oral Controlled-Absorption System: A Single-Dose, Randomized, Crossover Study in Healthy Adults

Jennifer Lee, Wenhui Zhang, Selina Moy,

Clinical Therapeutics

2013

22

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study

Dorien Groenendaal‐van de Meent, Martin den Adel, Sanne Rijnders,

Clinical Therapeutics

2016

20

Evaluation of the Pharmacokinetic Interaction Between the β<sub>3</sub>‐Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects

Walter Krauwinkel, Virginie Kerbusch, John Meijer,

Clinical Pharmacology in Drug Development

2013

17

Page 1